Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ING-1 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ING-1(heMAb) | DRUG | - |
Inclusion Criteria 1. Subject has adenocarcinomas of the ovary, breast, lung, prostate, colon or rectum. 2. Subject has an advanced metastatic adenocarcinoma that is either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist. 3. Subject has ...
ING-1 is an investigational small molecule being studied for the treatment of adenocarcinoma, a type of cancer that forms in glandular tissues. It is in Phase 1 clinical development for this oncology indication.
ING-1 is being developed by XOMA Royalty Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol XOMA.
ING-1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed.
ING-1 has one completed Phase 1 clinical trial, identified as NCT00051675, titled 'Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas.' The trial enrolled 30 participants in the United States.
ING-1 is described as a small molecule, but its Phase 1 clinical trial title refers to a monoclonal antibody. The drug is being studied for adenocarcinoma, and the trial enrolled 30 adults aged 18 years and older.